Frank Carter, MD
Family Medicine · Augusta, GANPI 1164464087
Payments from drug & device makers
Across 210 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$469
- Pfizer$359
- Novo Nordisk$288
- Amgen$188
- Bayer$170
- Lilly USA, LLC$170
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,374100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $469 |
| Pfizer | 26 | $359 |
| Novo Nordisk | 19 | $288 |
| Amgen | 12 | $188 |
| Bayer | 7 | $170 |
| Lilly USA, LLC | 11 | $170 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $167 |
| AstraZeneca | 9 | $134 |
| Amarin Pharma, Inc. | 8 | $124 |
| Boston Scientific | 4 | $121 |
| Dexcom, Inc. | 7 | $112 |
| Boehringer Ingelheim | 7 | $111 |
| Otsuka America Pharmaceutical, Inc. | 5 | $110 |
| Esperion Therapeutics, Inc. | 5 | $102 |
| Abbott | 6 | $94 |
| GSK | 5 | $83 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $78 |
| Novartis | 5 | $72 |
| E.r. Squibb & Sons, L.L.C. | 4 | $50 |
| Antares Pharma, Inc. | 3 | $46 |
| Sanofi Pasteur Inc. | 3 | $44 |
| Merck | 3 | $43 |
| Astellas Pharma US Inc | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Johnson & Johnson | 1 | $11 |
How this compares
$3,374 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 11 | $154,813 |
| NuplazidPimavanserin Tartrate | 28 | $136,833 |
| EliquisApixaban | 149 | $115,770 |
| RybelsusSemaglutide | 57 | $83,430 |
| OzempicSemaglutide | 44 | $72,753 |
| JanuviaSitagliptin Phosphate | 62 | $68,862 |
| JardianceEmpagliflozin | 68 | $65,701 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $49,312 |
| MounjaroTirzepatide | 25 | $48,702 |
| FarxigaDapagliflozin Propanediol | 22 | $25,628 |
| LinzessLinaclotide | 15 | $22,090 |
| MyrbetriqMirabegron | 17 | $21,388 |
| EntrestoSacubitril/Valsartan | 12 | $18,075 |
| XareltoRivaroxaban | 13 | $18,040 |
| Bydureon BciseExenatide Microspheres | 12 | $14,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $30 | $176,20028 claims |
| Novo NordiskRybelsus, Ozempic, Levemir | $288 | $159,596113 claims |
| PfizerEliquis | $359 | $115,770149 claims |
| MerckJanuvia | $43 | $68,86262 claims |
| Boehringer IngelheimJardiance | $111 | $65,70168 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $83 | $59,64786 claims |
| Lilly USA, LLCMounjaro, Humulin 70-30 | $170 | $53,90863 claims |
| AbbVieLinzess, Creon, Synthroid | $469 | $37,09951 claims |
| AstraZenecaFarxiga | $134 | $25,62822 claims |
| NovartisEntresto | $72 | $18,07512 claims |
| Johnson & JohnsonXarelto | $11 | $18,04013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Augusta
- Daron FerrisAugusta$186K
- David KriegelAugusta$36K
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.